KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Skin cancer and hyperthermia and radiotherapy - SAHARA: study protocol for a multicenter, two-arm, open-label, randomized controlled phase II non-inferiority trial. PMID 41430304 · Trials · 2025-Dec-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer. PMID 41430249 · Cost Eff Resour Alloc · 2025-Dec-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma. PMID 41429779 · Blood Cancer J · 2025-Dec-22 The report is an original results publication from a phase 2/3 trial in multiple myeloma, which is oncology, human, and involves a drug intervention. However, the abstract explicitly describes this as a 'subanalysis of the non-randomized phase 2 component,' which lacks randomization. Furthermore, the primary endpoint reported is renal response (a response rate), not a time-to-event efficacy endpoint such as OS, PFS, DFS, or Kaplan-Meier/HR analysis. The deterministic review signal for time-to-event is correctly false. Therefore, it does not meet the criteria for a definitive randomized trial with a time-to-event endpoint.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Efficacy and Safety of Traditional Chinese Medicine Qufenghuoxue Formula on Treating Peripheral Neuropathy Induced by Paclitaxel in Advanced Lung Cancer: A Randomized Clinical Trial. PMID 41428261 · Support Care Cancer · 2025-Dec-22 The study is an oncology RCT in humans with a drug intervention and is an original result report. However, it is excluded because the primary efficacy endpoint is not a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.), but a proportion of CIPN relief and recovery time. The phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the hazard ratio presented is for a secondary outcome (dose reduction/cessation), not for a primary key efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Transcutaneous Auricular Vagus Nerve Stimulation Reduces Inflammatory Biomarkers after Large Vessel Occlusion Stroke: Results of a Prospective Randomized Open-Label Blinded Endpoint Trial. PMID 41428140 · Transl Stroke Res · 2025-Dec-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Understanding shared decision-making among patients with limited health literacy: a realist review protocol. PMID 41423643 · Syst Rev · 2025-Dec-22 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer. PMID 41186991 · JCI Insight · 2025-Dec-22 The record describes a preplanned biomarker analysis from the CARD trial (Phase IV per publication type). It is not the primary report of the Phase III trial results; it is a biomarker subgroup analysis. Therefore, it does not meet the inclusion criteria for a definitive Phase III trial primary result report with drug intervention and time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study. PMID 41423595 · Breast Cancer Res · 2025-Dec-21 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial. PMID 41421991 · BMC Geriatr · 2025-Dec-20 The trial is a randomized controlled trial in oncology patients, but it does not meet key eligibility criteria. The phase is not specified as Phase III/IIIb or Phase II/III. The intervention is melatonin (a dietary supplement), not a drug. The primary endpoint is quality of life, and while survival is mentioned as a secondary objective, the results do not present a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier or HR analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study. PMID 41223345 · J Clin Oncol · 2025-Dec-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites. PMID 41600920 · Vaccines (Basel) · 2025-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lessons Learnt from the Belimumab Trials in Systemic Lupus Erythematosus. PMID 41515918 · Int J Mol Sci · 2025-Dec-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The impact of early nutritional care intervention on gastrointestinal function, immune function and nutritional indicators in patients after radical surgery for esophageal cancer: A single-center, observational study. PMID 41431032 · Medicine (Baltimore) · 2025-Dec-19 Excluded due to lack of drug intervention and lack of time-to-event efficacy endpoint. The study is a randomized trial of nutritional care, not a drug.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost and cost-effectiveness of attractive targeted sugar baits (ATSB) in the context of a phase III cluster randomized control trial in Western Province, Zambia. PMID 41420162 · Malar J · 2025-Dec-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
O04 Mission EB -mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: a randomised, double-blinded, placebo controlled, crossover trial. PMID 41412990 · Br J Dermatol · 2025-Dec-19 The record describes a Phase II crossover trial of a cell therapy (mesenchymal stromal cells) in pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a genetic disorder with cancer risk but not a primary malignancy trial. The main efficacy endpoints are disease severity scores, wound appearance, pain, itch, and quality of life, not time-to-event outcomes (OS, PFS, DFS, etc.). The abstract explicitly states 'Results will be discussed at the meeting', indicating this is a protocol or interim presentation without final results. The intervention is a cell product, not a conventional drug, and the phase is not Phase III/IIIb or definitive Phase II/III. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reconstruction after distal gastrectomy and alkaline gastritis: a multi-center three-arm randomized trial comparing Billroth-II, Billroth-II Braun, and Uncut Roux-en-Y (SDR-02). PMID 41417990 · Int J Surg · 2025-Dec-18 This is a randomized Phase III trial in human gastric cancer, but the intervention is purely surgical (reconstruction methods) with no drug component. The primary endpoint is the incidence of bile reflux at 3 months (a categorical outcome), not a time-to-event efficacy endpoint. Therefore, it does not meet the drug intervention or time-to-event criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy, safety and immunogenicity of a recombinant human papillomavirus bivalent (types 16, 18) vaccine in healthy 18-30-year-old Chinese women: a phase III, double-blind, randomized, controlled trial. PMID 41413453 · BMC Infect Dis · 2025-Dec-18 The study is a randomized, placebo-controlled Phase III trial of a drug (HPV vaccine) with an oncology indication (prevention of cervical neoplasia). However, the primary efficacy endpoint is the proportion developing CIN2+, a categorical outcome, not a time-to-event endpoint like OS, PFS, or DFS. No Kaplan-Meier curves, hazard ratios, or other time-to-event analyses are reported in the abstract. Therefore, it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Tolvaptan pharmacokinetics and pharmacodynamics in adolescents with autosomal dominant polycystic kidney disease. PMID 41407907 · Eur J Pediatr · 2025-Dec-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis. PMID 41406445 · N Engl J Med · 2025-Dec-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. PMID 41406444 · N Engl J Med · 2025-Dec-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Coagulation factor XI and coronary artery disease: is there room for factor XI inhibitors? PMID 41312611 · Pol Arch Intern Med · 2025-Dec-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL. PMID 40857670 · Blood · 2025-Dec-18 The abstract describes a biomarker/genetic analysis (LEF1 alterations) from Phase II/III T-ALL trial cohorts but does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, etc.) with Kaplan-Meier or HR results. It focuses on biological insights and treatment response associations, not definitive trial outcome data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fragility of Evidence for the Efficacy of Anti-Fracture Medications. PMID 40488289 · J Clin Endocrinol Metab · 2025-Dec-18 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Interrater reliability in the assessment of oral mucositis among patients receiving high-dose chemotherapy: a multicenter comparison between specialized dentists and registered nurses. PMID 41408611 · BMC Cancer · 2025-Dec-17 The report is a methodological sub-study (interrater reliability) from a Phase III oncology trial, not the primary efficacy analysis. It lacks a time-to-event efficacy endpoint and does not report original trial results for a drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study. PMID 41408264 · Nutr J · 2025-Dec-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term protection from naturally acquired immunity against hepatitis E virus reinfection. PMID 41407683 · Nat Commun · 2025-Dec-17 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study. PMID 41407426 · BMJ Open · 2025-Dec-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Ambulatory laparoscopic colorectal surgery management paradigm with initial experience: a prospective randomized clinical trial. PMID 41405332 · Int J Surg · 2025-Dec-17 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Tegileridine for moderate-to-severe acute pain following abdominal surgery: A randomized, double-blind, phase 3 clinical trial. PMID 41365300 · Cell Rep Med · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome. PMID 41321238 · Circulation · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial. PMID 41144242 · JAMA · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR. PMID 40892609 · J Am Coll Cardiol · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial. PMID 40864019 · J Am Coll Cardiol · 2025-Dec-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. PMID 41065506 · Clin Cancer Res · 2025-Dec-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparative Effectiveness of Text + Video vs Text Alone to Prompt Stool-Based Testing for Colorectal Cancer Screening. PMID 41042066 · Perm J · 2025-Dec-15 The study is an oncology-related randomized trial with a time-to-event endpoint, but it lacks a drug intervention and does not meet the phase criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ctDNA Longitudinal Analysis during Total Neoadjuvant Therapy and Nonoperative Management for Locally Advanced Rectal Cancer: A Biomarker Study from the NOMINATE Trial. PMID 40772855 · Clin Cancer Res · 2025-Dec-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse®) in Japanese Patients with Lambert-Eaton Myasthenic Syndrome (LMS-005 Study). PMID 40533232 · Intern Med · 2025-Dec-15 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population]. PMID 41486656 · Zhonghua Xue Ye Xue Za Zhi · 2025-Dec-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial. PMID 41392086 · Nat Commun · 2025-Dec-14 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A Double-Blind Randomized Active-Controlled Trial Evaluating the Short-Term Efficacy of a Single Intramuscular Injection of a Fixed-Dose Combination Product Containing Diclofenac and Thiocolchicoside in Patients with Acute Moderate to Severe Low Back Pain. PMID 41464730 · J Clin Med · 2025-Dec-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis. PMID 41463210 · Cancers (Basel) · 2025-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Photodynamic therapy: An alternative technique to cervical conization for cervical dysplasia. PMID 41389709 · Med · 2025-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of enteral Ecoimmunonutrition on immunological response, nutritional status and tolerance to treatment in gastrointestinal malignancy patients receiving chemotherapy. PMID 41387645 · Support Care Cancer · 2025-Dec-12 The study is a randomized controlled trial in oncology with a drug-containing intervention, but it lacks any explicit time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) or associated statistical results (Kaplan-Meier, HR). The reported outcomes are immunological, nutritional, quality of life, and preclinical tumor growth. Phase is not specified as III/IIIb or definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Immunotherapy for urological cancers in 2025]. PMID 41385769 · Magy Onkol · 2025-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The patient reported intraocular lens questionnaire (PR-ILQ): content validity, psychometric performance, and use in a regulated clinical trial to evaluate safety and effectiveness outcomes. PMID 41385130 · J Patient Rep Outcomes · 2025-Dec-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. PMID 41381424 · Signal Transduct Target Ther · 2025-Dec-12 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials. PMID 41381211 · RMD Open · 2025-Dec-11 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial. PMID 40557879 · Sleep · 2025-Dec-11 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transcatheter arterial chemoembolization with or without bevacizumab in hepatocellular carcinoma with portal vein invasion: a randomized trial. PMID 41373028 · Cancer Imaging · 2025-Dec-10 Study is a randomized trial with drug intervention and time-to-event endpoints, but the phase is not explicitly established as Phase III/IIIb or Phase II/III in the provided metadata, which is required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
An efficient single-arm Bayesian adaptive trial algorithm to evaluate de-intensified oncologic treatment. PMID 41372997 · Trials · 2025-Dec-10 The record describes a methodological paper for a Bayesian adaptive trial design, not a report of results from a randomized drug intervention trial. It is a single-arm design simulation/validation study, not a Phase II/III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -